Bridgette Collins-Burow, MD
Hematology & Oncology · New Orleans, LANPI 1942478805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Gilead at 27.7% of the total. 2025 is the largest year on record at $376, 5.6 times the $67 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 51 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$269
- Novartis$116
- Daiichi Sankyo Inc.$103
- Pfizer$74
- AstraZeneca$54
- Merck$54
- plus $301 from 12 others
What the payments were for
- Food & beverage$95999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $269 |
| Novartis | 6 | $116 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Pfizer | 4 | $74 |
| AstraZeneca(2 entities) | 3 | $54 |
| Merck | 3 | $54 |
| Genentech USA, Inc. | 3 | $47 |
| Amgen | 2 | $34 |
| Bristol Myers Squibb | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $14 |
How this compares
$971 in reported general payments places this provider in the 15th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 12 | $188,871 |
| Exemestane | 31 | $3,351 |
| Anastrozole | 106 | $1,800 |
| Tamoxifen Citrate | 12 | $384 |
| Letrozole | 21 | $240 |
| Alendronate Sodium | 13 | $138 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.